Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Details)

v3.20.2
Commitments and Contingencies - Additional Information (Details)
 3 Months Ended 6 Months Ended
Apr. 10, 2015
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
MilestonePayment
Jun. 30, 2020
EUR (€)
MilestonePayment
Jun. 30, 2017
USD ($)
Purchase Commitment            
Supply Commitment [Line Items]            
Purchase commitment non cancelable and cancelable       $ 10,508,000    
U.S | Cornell University | Neuromuscular Blocking Agents License Agreement            
Supply Commitment [Line Items]            
Regulatory approval and commercialization milestones           $ 5,000,000
European | Cornell University | Neuromuscular Blocking Agents License Agreement            
Supply Commitment [Line Items]            
Regulatory approval and commercialization milestones           $ 3,000,000
Maximum | Executive Officer            
Supply Commitment [Line Items]            
Aggregate annual base salaries of employment agreements       $ 1,327,000    
Recro            
Supply Commitment [Line Items]            
Number of days from the filing of plaintiff's opposition       30 days 30 days  
Recro | Alkermes Transaction            
Supply Commitment [Line Items]            
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones $ 140,000,000          
Recro | Alkermes Transaction | Regulatory Approval and Net Sales Milestones            
Supply Commitment [Line Items]            
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones $ 50,000,000          
Collaborative arrangements, milestone payments period 7 years          
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction            
Supply Commitment [Line Items]            
Collaborative Arrangements Milestone Payments upon Achievement of Regulatory and Sales Milestones       $ 10,000,000    
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, First Component            
Supply Commitment [Line Items]            
Business acquisition contingent consideration, first milestone payment     $ 5,000,000      
Business acquisition contingent consideration possible milestone payments   $ 5,000,000        
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Third Component            
Supply Commitment [Line Items]            
Minimum milestone payments percentage       60.00% 60.00%  
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component            
Supply Commitment [Line Items]            
Maximum royalty payment percentage       30.00% 30.00%  
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due, Following Regulatory Approval | Contingent Consideration, Second Component            
Supply Commitment [Line Items]            
Business acquisition contingent consideration possible milestone payments       $ 5,000,000    
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due, Beginning on First Anniversary of Regulatory Approval | Contingent Consideration, Second Component            
Supply Commitment [Line Items]            
Business acquisition contingent consideration possible milestone payments       $ 45,000,000    
Business acquisition, contingent consideration, number of equal annual milestone payments | MilestonePayment       7 7  
Business acquisition, contingent consideration, equal annual milestone payments       $ 6,400,000    
Recro | Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component            
Supply Commitment [Line Items]            
Royalty payment percentage       10.00% 10.00%  
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Second Component            
Supply Commitment [Line Items]            
Business acquisition, contingent consideration, milestone payments due period following regulatory approval       180 days 180 days  
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component            
Supply Commitment [Line Items]            
Royalty payment percentage       12.00% 12.00%  
Recro | Dexmedetomidine License Agreement            
Supply Commitment [Line Items]            
Contingent milestone payments, maximum       $ 23,017,000 € 20,500,000  
Amount of royalty payments due or payable       $ 0    
Recro | Dexmedetomidine License Agreement | Minimum            
Supply Commitment [Line Items]            
Percentage of royalty payments       10.00% 10.00%  
Recro | Dexmedetomidine License Agreement | Maximum            
Supply Commitment [Line Items]            
Percentage of royalty payments       20.00% 20.00%  
Recro | Fadolmidine License Agreement            
Supply Commitment [Line Items]            
Amount of royalty payments due or payable       $ 0    
Additional contingent milestones payment       $ 13,699,000 € 12,200,000  
Recro | Fadolmidine License Agreement | Minimum            
Supply Commitment [Line Items]            
Percentage of royalty payments       10.00% 10.00%  
Recro | Fadolmidine License Agreement | Maximum            
Supply Commitment [Line Items]            
Percentage of royalty payments       15.00% 15.00%